GHRP-2 Test Flags aGHD From Brain Injury With 9 ng/mL GH Cutoff
Background
Adult growth hormone deficiency (aGHD) has historically been attributed to hypothalamic-pituitary lesions, but traumatic brain injury (TBI) and subarachnoid hemorrhage (SAH) are increasingly recognized etiologies. The high population incidence of these brain injuries — combined with significant rates of hypopituitarism among survivors — implies that aGHD's public health burden is substantially underestimated. Standard provocative tests (insulin tolerance test, arginine, L-DOPA, glucagon) require a peak GH threshold of <3 ng/mL, yet carry limitations including hypoglycemia risk. A rapid, safe alternative that can identify patients missed by conventional criteria is needed, particularly for post-injury populations who may be medically fragile. The role of IGF-1 as a standalone biomarker is also complicated by its insensitivity in partial deficiency states.
Study Design
This paper presents a clinical review and diagnostic/treatment guideline summary for aGHD arising from brain injury. Diagnostic criteria and stimulation test thresholds were evaluated across multiple provocative testing modalities, including the insulin tolerance test, arginine test, L-DOPA test, glucagon test, and the GHRP-2 stimulation test. The GHRP-2 test was highlighted as a Japan-specific assay with a distinct GH cutoff. GH replacement dosing strategy, hormonal interaction profiles, and long-term safety data were also reviewed. No single controlled trial design, specific patient cohort size, or prospective enrollment is described in the abstract.
Results
Conventional provocative tests (insulin tolerance test, arginine, L-DOPA, glucagon) define aGHD by a peak GH level under 3 ng/mL. The GHRP-2 stimulation test, currently available only in Japan, uses a higher peak GH cutoff of under 9 ng/mL and is characterized as both safe and quick for assessing GH secretory function. IGF-1 levels that are low may support a diagnosis of GHD in the presence of hypopituitarism, but a normal IGF-1 does not exclude GHD. GH replacement therapy requires dose adjustment aligned with normal physiology to minimize adverse effects and may alter the metabolism of thyroid hormone and glucocorticoid, increasing exogenous hormone requirements.
Long-term GH replacement therapy has been reported to improve both the morbidity and mortality of aGHD, though the abstract states no evidence that GH replacement increases risk of tumor recurrence, de-novo neoplasm, or serious cardiovascular disease.
The public health impact of post-TBI/SAH aGHD is described as larger than generally recognized given the high incidence of these injuries.
Key Findings
- Conventional GH stimulation tests define aGHD by peak GH <3 ng/mL (insulin tolerance, arginine, L-DOPA, glucagon).
- GHRP-2 stimulation test uses a higher diagnostic cutoff of peak GH <9 ng/mL; currently Japan-only.
- Normal IGF-1 level does not rule out GHD; low IGF-1 supports GHD only in context of hypopituitarism.
- Long-term GH replacement reported to improve morbidity and mortality in aGHD patients.
- TBI and subarachnoid hemorrhage are emerging etiologies making aGHD's public health burden larger than generally recognized.
Why It Matters
Clinicians managing TBI or SAH survivors should consider routine GH axis screening, as hypopituitarism and aGHD are far more prevalent in this population than traditionally assumed. The GHRP-2 test's <9 ng/mL cutoff provides a distinct diagnostic threshold that practitioners must apply correctly — using conventional cutoffs for this assay would misclassify patients. GH replacement in aGHD requires active monitoring of thyroid and glucocorticoid replacement doses, since GH alters their metabolism and can precipitate apparent deficiency of co-administered hormones. Long-term safety surveillance for neoplasia and cardiovascular outcomes remains obligatory despite the absence of confirmed causal risk signals in current data.
